The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 04, 2021

Filed:

Feb. 23, 2017
Applicants:

Biolinerx Ltd., ModiIn, IL;

Biokine Therapeutics Ltd., Nes Ziona, IL;

Inventors:

Yaron Pereg, Shoham, IL;

Amnon Peled, Tel-Aviv, IL;

Assignees:

BioLmeRx Ltd., ModiIn, IL;

Biokine Therapeutics Ltd., Nes Ziona, IL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/10 (2006.01); A61K 31/7068 (2006.01); G01N 33/569 (2006.01); G01N 33/574 (2006.01); A61K 45/06 (2006.01); C07K 7/08 (2006.01); A61P 35/02 (2006.01);
U.S. Cl.
CPC ...
A61K 38/10 (2013.01); A61K 31/7068 (2013.01); A61K 45/06 (2013.01); A61P 35/02 (2018.01); C07K 7/08 (2013.01); G01N 33/56972 (2013.01); G01N 33/57426 (2013.01); G01N 2333/7158 (2013.01); G01N 2800/52 (2013.01);
Abstract

A method of treating acute myeloid leukemia (AML), including the steps of (i) measuring a density of blast cells in the peripheral blood and the bone marrow of a subject with AML; (ii) administering to the subject a CXCR4 antagonist; and (iii) administering to the subject a therapeutically effective amount of the CXCR4 antagonist and a therapeutically effective amount of a chemotherapeutic agent, if the blast cell density in the peripheral blood is less than 10% of the total peripheral white blood cells, or at least five-fold lower than the blast cell density in the bone marrow, or at least two-fold higher one day or more following step (ii).


Find Patent Forward Citations

Loading…